Coats on for Starpharma
Tuesday, 09 September, 2008
Starpharma [ASX: SPL] has licensed the marketing rights to its VivaGel coated condom to SSL International, owners of the market-leading Durex condom brand.
Under the agreement, SSL has been granted the right to marketing the VivaGel condom in most of the world, including Europe and the US.
The agreement could be worth at least $100 million in royalties, milestone payments and development support to Starpharma.
Starpharma is continuing to develop VivaGel as an applicator-delivered vaginal product designed to help women protect themselves from HIV and genital herpes.
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
